一种用于精准免疫肿瘤学的首创、非侵入性、免疫动力学生物标志物方法。
A first-in-class, non-invasive, immunodynamic biomarker approach for precision immuno-oncology.
机构信息
Department of Cellular & Molecular Medicine, Laboratory of Cell Stress & Immunity, KU Leuven, Belgium.
Department of Oncology, Leuven Cancer Institute, Laboratory of Tumor Immunology and Immunotherapy, KU Leuven, Belgium.
出版信息
Oncoimmunology. 2022 Jan 10;11(1):2024692. doi: 10.1080/2162402X.2021.2024692. eCollection 2022.
Non-invasive, immuno-dynamic, biomarkers positioned in cancer patient's blood milieu with immuno-oncological applications are rare. We recently established a "first-in-class" serum functional immunodynamics status (sFIS) assay, wherein assessment of serum-induced myeloid NFkB and/or interferon (IFN) response-signaling can be performed to "mimic" patient's serum immune-biology. This modality has clear implications for anticipating patient prognosis and immunotherapy-relevant stratification.
目前，在癌症患者的血液环境中，具有免疫肿瘤学应用的无创、免疫动力学、生物标志物非常罕见。我们最近建立了一种“首创”的血清功能免疫动力学状态（sFIS）检测方法，通过评估血清诱导的髓系 NFkB 和/或干扰素（IFN）反应信号传导，可以“模拟”患者的血清免疫生物学。这种方法对预测患者预后和免疫治疗相关分层具有明确的意义。
Zotero 插件